#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	11480	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2024	557.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1676	1676	T	648	T,C	620,9	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	11480	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2024	557.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1410	1410	C	691	C	682	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	20830	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3748	551.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1803	1803	A	654	A	646	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	20830	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3748	551.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2437	2437	C	644	C	629	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	20830	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3748	551.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2511	2511	A	676	A	666	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	20830	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3748	551.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	3063	3063	C	643	C	637	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1588	folP	855	855	100.0	folP.l6.c4.ctg.1	1675	94.4	1	SNP	p	R229S	1	.	.	685	687	AGC	997	999	AGC	129;130;131	A,G;G;C	125,1;128;131	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4426	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3411	128.6	1	SNP	p	S91F	1	.	.	271	273	TTC	606	608	TTC	148;146;147	T;T,C;C	147;144,2;146	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4426	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3411	128.6	1	SNP	p	G95N	0	.	.	283	285	GGC	618	620	GGC	141;138;135	G;G,A;C	138;136,2;134	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4426	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3411	128.6	1	SNP	p	D95G	1	.	.	283	285	GGC	618	620	GGC	141;138;135	G;G,A;C	138;136,2;134	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	1400	mtrR	633	633	100.0	mtrR.l6.c4.ctg.1	1279	108.6	1	SNP	p	G45D	1	.	.	133	135	GAC	461	463	GAC	163;164;163	G;A;C	163;162;162	mtrR.WHO_K_01388:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	692	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1119	61.0	0	.	n	.	0	A197.	DEL	197	197	A	668	668	A	145	A	143	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3848	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2988	127.6	1	SNP	p	D86N	1	D86N	NONSYN	256	258	GAC	637	639	AAC	153;154;154	A,G;A;C	144,5;152;154	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3848	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2988	127.6	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1531	1533	ATC	151;148;150	A,G,C;T;C,T	147,2,1;144;149,1	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3848	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2988	127.6	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1684	1686	GCA	143;143;147	G;C,T;A,G	136;135,2;131,1	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3848	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2988	127.6	1	SNP	p	S87W	0	.	.	259	261	AGT	640	642	AGT	160;161;160	A;G;T	157;160;152	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3848	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2988	127.6	1	SNP	p	S87R	0	.	.	259	261	AGT	640	642	AGT	160;161;160	A;G;T	157;160;152	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3848	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2988	127.6	1	SNP	p	S87I	0	.	.	259	261	AGT	640	642	AGT	160;161;160	A;G;T	157;160;152	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3848	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2988	127.6	1	SNP	p	S88P	0	.	.	262	264	TCC	643	645	TCC	161;161;160	T,G;C;C	156,1;155;156	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3204	parE	1986	1986	99.9	parE.l15.c4.ctg.1	2619	120.7	0	.	p	.	0	V89A	NONSYN	265	267	GTC	635	637	GCC	132;136;136	G;C,T;C,T	123;127,3;125,2	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3204	parE	1986	1986	99.9	parE.l15.c4.ctg.1	2619	120.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1598	1600	GGC	157;159;158	G;G;C	155;157;155	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.002	penA.2.002	1	1	27	3048	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2509	119.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1286	1288	GCA	175;174;170	G;C;A	172;169;168	penA.2.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3048	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2509	119.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1289	1291	ATC	171;172;174	A;T;C	170;171;170	penA.2.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3048	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2509	119.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1301	1303	GTG	180;177;178	G;T,A;G	175;170,1;174	penA.2.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3048	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2509	119.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1301	1303	GTG	180;177;178	G;T,A;G	175;170,1;174	penA.2.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3048	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2509	119.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1805	1807	ACC	123;124;124	A;C;C	118;122;121	penA.2.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3048	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2509	119.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1859	1861	GCG	131;132;131	G;C,G;G	121;114,2;125	penA.2.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3048	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2509	119.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1859	1861	GCG	131;132;131	G;C,G;G	121;114,2;125	penA.2.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3048	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2509	119.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1982	1984	GGC	89;88;88	G;G;C,T	89;87;84,1	penA.2.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3048	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2509	119.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1991	1993	GGC	85;85;83	G,A;G;C	79,1;84;81	penA.2.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3048	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2509	119.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2009	2011	CCG	76;76;75	C,G;C;G,T,C	69,1;65;60,1,1	penA.2.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	4438	ponA	2397	2397	99.87	ponA.l15.c4.ctg.1	3191	138.0	0	.	p	.	0	A375T	NONSYN	1123	1125	GCG	1559	1561	ACG	151;151;151	A,G;C;G,T	133,3;148;147,1	.	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	4438	ponA	2397	2397	99.87	ponA.l15.c4.ctg.1	3191	138.0	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1697	1699	CTG	162;162;163	C;T;G	149;151;147	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1972	porA	1146	1146	99.74	porA.l15.c4.ctg.1	1872	104.0	0	.	p	.	0	S22G	NONSYN	64	66	AGC	340	342	GGC	116;116;120	G,A;G;C	113,1;113;116	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1972	porA	1146	1146	99.74	porA.l15.c4.ctg.1	1872	104.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	522	522	C	137	C	127	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2246	porB1b	1047	1047	98.29	porB1b.l15.c17.ctg.1	1452	152.5	0	.	p	.	0	T26A	NONSYN	76	78	ACC	333	335	GCC	180;177;180	G,A;C;C	175,1;176;178	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2246	porB1b	1047	1047	98.29	porB1b.l15.c17.ctg.1	1452	152.5	0	.	p	.	0	N38E	NONSYN	112	114	AAT	369	371	GAA	173;172;171	G;A,C;A	167;166,1;166	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2246	porB1b	1047	1047	98.29	porB1b.l15.c17.ctg.1	1452	152.5	0	.	p	.	0	K41D	NONSYN	121	123	AAA	378	380	GAC	167;167;169	G;A;C	159;162;164	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2246	porB1b	1047	1047	98.29	porB1b.l15.c17.ctg.1	1452	152.5	0	.	p	.	0	N134D	NONSYN	400	402	AAT	657	659	GAT	172;172;174	G;A;T,G	168;168;169,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2246	porB1b	1047	1047	98.29	porB1b.l15.c17.ctg.1	1452	152.5	0	.	p	.	0	P175S	NONSYN	523	525	CCA	780	782	TCA	152;153;153	T;C;A	146;148;149	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2246	porB1b	1047	1047	98.29	porB1b.l15.c17.ctg.1	1452	152.5	0	.	p	.	0	A218I	NONSYN	652	654	GCC	909	911	ATC	196;198;197	A;TCCCC,TCCC;C	192;186,1;189	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2246	porB1b	1047	1047	98.29	porB1b.l15.c17.ctg.1	1452	152.5	0	.	p	.	0	F222L	NONSYN	664	666	TTT	921	923	CTT	193;192;192	C,T;T;T	188,1;189;189	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2246	porB1b	1047	1047	98.29	porB1b.l15.c17.ctg.1	1452	152.5	0	.	p	.	0	G255_T256insS	INS	763	763	G	1020	1020	G	171	G	169	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2246	porB1b	1047	1047	98.29	porB1b.l15.c17.ctg.1	1452	152.5	0	.	p	.	0	N260S	NONSYN	778	780	AAT	1038	1040	AGT	178;179;179	A;G,A;T	177;175,3;176	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2246	porB1b	1047	1047	98.29	porB1b.l15.c17.ctg.1	1452	152.5	0	.	p	.	0	D333E	NONSYN	997	999	GAC	1257	1259	GAA	201;203;203	G;A;A	199;200;201	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2246	porB1b	1047	1047	98.29	porB1b.l15.c17.ctg.1	1452	152.5	1	SNP	p	G120K	1	.	.	358	360	AAG	615	617	AAG	156;156;158	A,G;A,G;G,T	153,1;154,1;154,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2246	porB1b	1047	1047	98.29	porB1b.l15.c17.ctg.1	1452	152.5	1	SNP	p	D121N	0	.	.	361	363	GAC	618	620	GAC	160;161;163	G;A,C;C	156;158,1;162	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2246	porB1b	1047	1047	98.29	porB1b.l15.c17.ctg.1	1452	152.5	1	SNP	p	A121D	1	.	.	361	363	GAC	618	620	GAC	160;161;163	G;A,C;C	156;158,1;162	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	7838	rpoB	4179	4179	99.95	rpoB.l6.c4.ctg.1	4859	160.1	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2027	2029	AAT	140;144;145	A;A;T	140;142;143	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	996	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1097	90.0	1	SNP	p	V57M	1	.	.	169	171	ATG	632	634	ATG	184;184;183	A;T;G	182;180;180	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
